The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology

EMBO Mol Med. 2018 Jan;10(1):32-47. doi: 10.15252/emmm.201707825.

Abstract

Alzheimer's disease is a devastating neurodegenerative disease eventually leading to dementia. An effective treatment does not yet exist. Here we show that oral application of the compound anle138b restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology. At the mechanistic level, we provide evidence that anle138b blocks the activity of conducting Aβ pores without changing the membrane embedded Aβ-oligomer structure. In conclusion, our data suggest that anle138b is a novel and promising compound to treat AD-related pathology that should be investigated further.

Keywords: Alzheimer's disease; Aβ channels; amyloid pathology; gene expression; membrane pores.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / genetics
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Benzodioxoles / pharmacology
  • Benzodioxoles / therapeutic use*
  • Disease Models, Animal
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuronal Plasticity / drug effects
  • Phenotype
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Spatial Memory / drug effects
  • Transcriptome / drug effects

Substances

  • 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole
  • Amyloid beta-Peptides
  • Benzodioxoles
  • Pyrazoles